Humulin M3 (Mistura M3) (Insulin Human (Rdna))

Humulin M3 is indicated for the management of blood glucose in patients with diabetes mellitus, providing basal insulin coverage to maintain fasting and between‑meal glucose levels.

• Type 1 diabetes mellitus as part of a basal insulin regimen.
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct therapy in combination with rapid‑acting insulin analogues.
• Use in pediatric patients when a long‑acting insulin is needed.
• Situations where a stable, predictable insulin profile is preferred.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering endogenous glucose production. These actions collectively reduce circulating glucose concentrations and support metabolic homeostasis.

Like all insulin preparations, Humulin M3 may be associated with adverse reactions that vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed, carbohydrate intake is reduced, or physical activity is increased.
• Injection site reactions such as redness, swelling, itching, or a small lump.
• Lipodystrophy presenting as localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at the injection site.
• Transient weight gain related to improved glycemic control and fluid retention.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, or loss of consciousness, requiring immediate assistance.
• Allergic reactions ranging from urticaria and angio‑edema to anaphylaxis.
• Edema or fluid retention leading to peripheral swelling, particularly in the lower extremities.
• Rare cases of insulin antibody formation causing unpredictable glucose response and possible resistance.

When prescribing or using Humulin M3, clinicians and patients should observe several precautionary measures to minimize risks and ensure safe therapy.

• Monitor blood glucose frequently, especially during dose initiation, changes, or illness.
• Adjust doses in renal or hepatic impairment, as insulin clearance may be reduced.
• Use caution in pregnant or breastfeeding individuals; benefits should outweigh potential risks.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Consider the risk of lipodystrophy; rotate injection sites regularly.
• Review concomitant medications that may potentiate hypoglycemia.

Humulin M3 can interact with other medicines, altering its glucose‑lowering effect or increasing the likelihood of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulin or insulin analogues without dose adjustment.
• Combination with sulfonylureas or meglitinides when excessive hypoglycemia risk is present.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can raise blood glucose and require higher insulin doses.
• Diuretics, especially thiazides, that may affect potassium balance and glucose control.
• Oral contraceptives or hormone replacement therapy, which can modify insulin sensitivity.
• Alcohol, which can cause delayed hypoglycemia after insulin administration.